Quantcast
Last updated on April 18, 2014 at 10:39 EDT

Latest Wilson's disease Stories

2014-04-16 04:21:57

STOCKHOLM, April 16, 2014 /PRNewswire/ -- Wilson Therapeutics, a biopharmaceutical company, today announced that it has closed a $40 million Series B financing co-led by new investors, Abingworth LLP and MVM Life Science Partners LLP ("MVM"). The company's founding investor, HealthCap, also participated in the round. "We are pleased with this significant support from our new as well as existing investors, who represent some of the most experienced in the global life sciences...

2012-02-07 14:49:41

The first European Clinical Practice Guidelines (CPGs) for the diagnosis and management of Wilson's disease are published today by the European Association for the Study of the Liver (EASL) on the EASL website -- www.easl.eu.(1) Developed to assist physicians and healthcare providers in the clinical decision making process, the guidelines describe best practice for the diagnosis and treatment of patients with Wilson's disease -- a rare genetic(2) disorder that, if left untreated, is fatal....

2010-10-12 05:00:00

ANN ARBOR, Mich., Oct. 12 /PRNewswire/ -- Adeona Pharmaceuticals, Inc., (Amex: AEN) announced five scientific publications on the role of copper toxicity and zinc deficiency in Alzheimer's disease and cognitive decline. The author of all these publications is Adeona's scientific founder and consultant, George J. Brewer, M.D., the Morton S. and Henrietta Sellner Emeritus Professor of Human Genetics and Internal Medicine at the University of Michigan. The first two publications describe the...

2010-04-08 12:50:18

As a result of the rarity of Wilson disease (WD) and the fact that liver biopsy is not performed routinely during follow-up, unless clinically indicated, the progression and timing of the liver pathology and its correlation with different anti-copper treatments or aminotransferase levels are poorly characterized. Previous studies have demonstrated the possibility of improvement of steatosis and inflammation grade, and of fibrosis stage during long-term follow-up. However, studies on serial...

2009-11-26 14:24:55

Crystal structure shows how drug disables harmful copper in cells The copper sequestering drug tetrathiomolybdate (TM) has been shown in studies to be effective in the treatment of Wilson disease, a disease caused by an overload of copper, and certain metastatic cancers. That much is known. Very little, however, is known about how the drug works at the molecular level. A new study led by Northwestern University researchers now has provided an invaluable clue: the three-dimensional structure...

2007-11-14 09:00:14

Pipex Pharmaceuticals, Inc. (AMEX: PP) ("Pipex"), a specialty pharmaceutical company developing innovative late-stage drug candidates for the treatment of neurologic and fibrotic diseases, announced clinical results of Alzheimer's disease test using FreeBound, Pipex's proprietary pharmacodiagnostic device for measurement of serum free and total copper. Dr. David A. Newsome was also highlighted on a medical news segment by New Orleans CBS news affiliate, WWLTV channel 4, entitled, "Copper,...

2007-04-30 09:00:49

Pipex Pharmaceuticals, Inc. (OTCBB: PPEX) ("Pipex"), a specialty pharmaceutical company developing innovative late-stage drug candidates for the treatment of neurologic and fibrotic diseases, announced today that it presented two oral presentations at the Annual Wilson's Disease Association (WDA) Conference in New York on April 28th. The presentations entitled "Tetrathiomolybdate for Neurological Initial Presenting Wilson's Disease - an Industry Drug Development Perspective" and "Direct...